ArticleFrontiers in oncology2026
Next-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early failure less than 12 months (POD12) of frontline R-CHOP chemo-immunotherapy in very poor outcomes and requires alternative therapy in patients with Diffuse large B-cell lymphoma (DLBCL). Aim: We aim to evaluate the association of gene alterations and clinical factors with POD12. Methods: The panel included 103 genes that were examined in 26 patients with newly diagnosed DLBCL treated with standard R-CHOP chemo-immunotherapy in the frontline setting therapy using next-generation sequencing. The association of clinical features and gene alterations with early progression was analyzed. Results: POD12 group (n=12) was related to poorer OS with a hazard ratio (HR) of 12.13 (95% confidence interval [CI] 2.34-62.78, p=0.0029). Genes mutated in 96.15% of patients (25/26) were grouped into 11 specific pathways, and the POD12 subtype was mostly characterized by mutations in the epigenetic modulation pathway (33.32% of total variation) and apoptosis/cell cycle/autophagy pathway (20.83% of total variation), whereas the no-POD12 subtype is mostly characterized by mutations in the epigenetic modulation pathway (40.66% of total variation). CD79B mutation frequency was significantly increased in the no-POD12 group compared with the POD12 group (50.00% vs 8.33%, p=0.0357). Not achieving complete response (CR) during interim treatment response was found to be significantly associated with the occurrence of POD12 (p=0.0214). Conclusions: CD79B wide-type and not achieving CR during interim responses evaluation correlate with POD12. These findings provide a basis for the development of optimal alternative therapies in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.